Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

Core Insights - Keros Therapeutics, Inc. announced additional data from its Phase 1 clinical trial of rinvatercept (KER-065), highlighting its potential in treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [1][2] Clinical Development - The Phase 1 trial was a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics of rinvatercept in healthy adult male volunteers [3] - Initial topline data from the trial was reported in March 2025, indicating that rinvatercept was well-tolerated at all evaluated dose levels, with no serious adverse events reported [4] Mechanism of Action - Rinvatercept demonstrated effects consistent with activin and myostatin inhibition, leading to increased muscle mass, decreased fat mass, and improved bone mineral density [4] - Proteomic data indicated that rinvatercept may mitigate fibrosis and inflammation, aligning with preclinical observations of its anti-fibrotic and anti-inflammatory effects [5] Future Trials - Keros plans to advance rinvatercept into two Phase 2 clinical trials targeting DMD and ALS, reinforcing its commitment to developing this therapeutic [2] Product Overview - Rinvatercept is designed as a ligand trap to inhibit the negative regulators of muscle and bone mass, aiming to improve muscle regeneration, increase muscle size and strength, and enhance bone health [6] - The company is also developing elritercept for treating cytopenias in patients with myelodysplastic syndrome and myelofibrosis [8]